Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences


Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the following upcoming conferences:

A live audio webcast of the presentations will be available on the Investors section of the company's website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket") is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases. Rocket's clinical programs using LVV-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket's first clinical program using AAV-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rocket's pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit www.rocketpharma.com.


These press releases may also interest you

at 06:10
Nextracker Launches Industry's First Low Carbon Solar Tracker Solution
Nextracker , a global provider of intelligent solar tracker and software solutions, today announced the availability of its flagship NX Horizontm solar tracker system with up to 35% lower carbon footprint. Marking a significant milestone for solar...

at 06:10
Rasa Recognized as a Representative Vendor in Gartner® Market Guide for Conversational AI Solutions
Rasa, a leader in generative conversational AI, proudly announces its recognition as a Representative Vendor in the Gartner® Market Guide for Conversational AI Solutions. Rasa believes this acknowledgment highlights its pivotal role in the future of...

at 06:10
Amazon Introduces Low-Cost Grocery Delivery Subscription for Prime Members and Customers Using EBT
Amazon today announced a new grocery delivery subscription benefit now available to Prime members and customers using EBT in more than 3,500 cities and towns across the U.S. At $9.99 per month for Prime members, this subscription offers unlimited...

at 06:10
IDTechEx Asks Where SMRs Will Fit in the Energy Ecosystem
Nuclear SMRs (small modular reactors) aim to take advantage of assembly line production to reduce cost and construction time compared to the large reactors that form the bulk of today's nuclear fleet. Their smaller size and frequent use of advanced...

at 06:06
Top 2024 Infrastructure and Operations Priorities for UK Leaders Published in Report by Info-Tech Research Group
As...

at 06:05
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BeiGene, Ltd. , a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use....

More news about Science and technology...


News published on and distributed by: